Cargando…
Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients—COVIDOUT study
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040439/ https://www.ncbi.nlm.nih.gov/pubmed/35512712 http://dx.doi.org/10.1016/j.ccell.2022.04.016 |
_version_ | 1784694336587300864 |
---|---|
author | Schönlein, Martin Wrage, Victoria Ghandili, Susanne Mellinghoff, Sibylle C. Brehm, Thomas Theo Leypoldt, Lisa B. Utz, Nils Schrader, Roland M. Alsdorf, Winfried Börschel, Niklas Bußmann, Lara Schönrock, Martin Perlick, Dorothea Schön, Gerhard Verpoort, Karl Lütgehetmann, Marc Schulze zur Wiesch, Julian Weisel, Katja C. Bokemeyer, Carsten Schafhausen, Philippe Sinn, Marianne |
author_facet | Schönlein, Martin Wrage, Victoria Ghandili, Susanne Mellinghoff, Sibylle C. Brehm, Thomas Theo Leypoldt, Lisa B. Utz, Nils Schrader, Roland M. Alsdorf, Winfried Börschel, Niklas Bußmann, Lara Schönrock, Martin Perlick, Dorothea Schön, Gerhard Verpoort, Karl Lütgehetmann, Marc Schulze zur Wiesch, Julian Weisel, Katja C. Bokemeyer, Carsten Schafhausen, Philippe Sinn, Marianne |
author_sort | Schönlein, Martin |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-9040439 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90404392022-04-26 Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients—COVIDOUT study Schönlein, Martin Wrage, Victoria Ghandili, Susanne Mellinghoff, Sibylle C. Brehm, Thomas Theo Leypoldt, Lisa B. Utz, Nils Schrader, Roland M. Alsdorf, Winfried Börschel, Niklas Bußmann, Lara Schönrock, Martin Perlick, Dorothea Schön, Gerhard Verpoort, Karl Lütgehetmann, Marc Schulze zur Wiesch, Julian Weisel, Katja C. Bokemeyer, Carsten Schafhausen, Philippe Sinn, Marianne Cancer Cell Letter Elsevier Inc. 2022-06-13 2022-04-26 /pmc/articles/PMC9040439/ /pubmed/35512712 http://dx.doi.org/10.1016/j.ccell.2022.04.016 Text en © 2022 Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Letter Schönlein, Martin Wrage, Victoria Ghandili, Susanne Mellinghoff, Sibylle C. Brehm, Thomas Theo Leypoldt, Lisa B. Utz, Nils Schrader, Roland M. Alsdorf, Winfried Börschel, Niklas Bußmann, Lara Schönrock, Martin Perlick, Dorothea Schön, Gerhard Verpoort, Karl Lütgehetmann, Marc Schulze zur Wiesch, Julian Weisel, Katja C. Bokemeyer, Carsten Schafhausen, Philippe Sinn, Marianne Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients—COVIDOUT study |
title | Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients—COVIDOUT study |
title_full | Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients—COVIDOUT study |
title_fullStr | Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients—COVIDOUT study |
title_full_unstemmed | Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients—COVIDOUT study |
title_short | Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients—COVIDOUT study |
title_sort | risk factors for poor humoral response to primary and booster sars-cov-2 vaccination in hematologic and oncological outpatients—covidout study |
topic | Letter |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040439/ https://www.ncbi.nlm.nih.gov/pubmed/35512712 http://dx.doi.org/10.1016/j.ccell.2022.04.016 |
work_keys_str_mv | AT schonleinmartin riskfactorsforpoorhumoralresponsetoprimaryandboostersarscov2vaccinationinhematologicandoncologicaloutpatientscovidoutstudy AT wragevictoria riskfactorsforpoorhumoralresponsetoprimaryandboostersarscov2vaccinationinhematologicandoncologicaloutpatientscovidoutstudy AT ghandilisusanne riskfactorsforpoorhumoralresponsetoprimaryandboostersarscov2vaccinationinhematologicandoncologicaloutpatientscovidoutstudy AT mellinghoffsibyllec riskfactorsforpoorhumoralresponsetoprimaryandboostersarscov2vaccinationinhematologicandoncologicaloutpatientscovidoutstudy AT brehmthomastheo riskfactorsforpoorhumoralresponsetoprimaryandboostersarscov2vaccinationinhematologicandoncologicaloutpatientscovidoutstudy AT leypoldtlisab riskfactorsforpoorhumoralresponsetoprimaryandboostersarscov2vaccinationinhematologicandoncologicaloutpatientscovidoutstudy AT utznils riskfactorsforpoorhumoralresponsetoprimaryandboostersarscov2vaccinationinhematologicandoncologicaloutpatientscovidoutstudy AT schraderrolandm riskfactorsforpoorhumoralresponsetoprimaryandboostersarscov2vaccinationinhematologicandoncologicaloutpatientscovidoutstudy AT alsdorfwinfried riskfactorsforpoorhumoralresponsetoprimaryandboostersarscov2vaccinationinhematologicandoncologicaloutpatientscovidoutstudy AT borschelniklas riskfactorsforpoorhumoralresponsetoprimaryandboostersarscov2vaccinationinhematologicandoncologicaloutpatientscovidoutstudy AT bußmannlara riskfactorsforpoorhumoralresponsetoprimaryandboostersarscov2vaccinationinhematologicandoncologicaloutpatientscovidoutstudy AT schonrockmartin riskfactorsforpoorhumoralresponsetoprimaryandboostersarscov2vaccinationinhematologicandoncologicaloutpatientscovidoutstudy AT perlickdorothea riskfactorsforpoorhumoralresponsetoprimaryandboostersarscov2vaccinationinhematologicandoncologicaloutpatientscovidoutstudy AT schongerhard riskfactorsforpoorhumoralresponsetoprimaryandboostersarscov2vaccinationinhematologicandoncologicaloutpatientscovidoutstudy AT verpoortkarl riskfactorsforpoorhumoralresponsetoprimaryandboostersarscov2vaccinationinhematologicandoncologicaloutpatientscovidoutstudy AT lutgehetmannmarc riskfactorsforpoorhumoralresponsetoprimaryandboostersarscov2vaccinationinhematologicandoncologicaloutpatientscovidoutstudy AT schulzezurwieschjulian riskfactorsforpoorhumoralresponsetoprimaryandboostersarscov2vaccinationinhematologicandoncologicaloutpatientscovidoutstudy AT weiselkatjac riskfactorsforpoorhumoralresponsetoprimaryandboostersarscov2vaccinationinhematologicandoncologicaloutpatientscovidoutstudy AT bokemeyercarsten riskfactorsforpoorhumoralresponsetoprimaryandboostersarscov2vaccinationinhematologicandoncologicaloutpatientscovidoutstudy AT schafhausenphilippe riskfactorsforpoorhumoralresponsetoprimaryandboostersarscov2vaccinationinhematologicandoncologicaloutpatientscovidoutstudy AT sinnmarianne riskfactorsforpoorhumoralresponsetoprimaryandboostersarscov2vaccinationinhematologicandoncologicaloutpatientscovidoutstudy |